Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer
NCT05766371Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Dec 2023
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of California, San Francisco. Primary endpoint: Radiographic Progression-Free Survival at 12 months. Started Dec 2023; status: recruiting.
02
Drugs
pembrolizumablutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05766371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766371.